Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Adenocarcinoma × Nivolumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 241 Carcinoma, Non-Small-Cell Lung 212 Carcinoma, Renal Cell 130 Neoplasm Metastasis 92 Neoplasms 87 Squamous Cell Carcinoma of Head and Neck 78 Carcinoma, Hepatocellular 75 Colorectal Neoplasms 70 Lung Neoplasms 66 Stomach Neoplasms 53 Pancreatic Neoplasms 49 Carcinoma, Transitional Cell 41 Hodgkin Disease 40 Head and Neck Neoplasms 39 Urinary Bladder Neoplasms 36 Breast Neoplasms 36 Ovarian Neoplasms 34 Triple Negative Breast Neoplasms 31 Small Cell Lung Carcinoma 29 Sarcoma 29 Brain Neoplasms 29 Kidney Neoplasms 28 Prostatic Neoplasms 27 Glioblastoma 27 Recurrence 26 Multiple Myeloma 22 Esophageal Neoplasms 22 Skin Neoplasms 20 Lymphoma 20 Uveal Melanoma 19

Interventions

Gemcitabine 10 Albumin-Bound Paclitaxel 7 Taxes 5 130-nm albumin-bound paclitaxel 5 Fluorouracil 4 Radiotherapy, Intensity-Modulated 3 Oxaliplatin 3 dehydroftorafur 2 Radiotherapy 2 Leucovorin 2 Irinotecan 2 tocilizumab 1 selicrelumab 1 niraparib 1 irinotecan sucrosofate 1 indusatumab 1 folfirinox 1 durvalumab 1 cobimetinib 1 atezolizumab 1 Tiragolumab 1 Surgical Procedures, Operative 1 S 1 (combination) 1 Resistance Training 1 Radiotherapy, Image-Guided 1 Radiotherapy, Conformal 1 Radiosurgery 1 Panitumumab 1 Pancreatectomy 1 PEGPH20 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03404960 2025-10-10

Parpvax

University of Pennsylvania

Phase 1/2 Completed

104 enrolled 11 charts

Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡